Riverhead Capital Management LLC lessened its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 33.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,717 shares of the biopharmaceutical company’s stock after selling 2,913 shares during the period. Riverhead Capital Management LLC’s holdings in Alexion Pharmaceuticals were worth $749,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. Steward Partners Investment Advisory LLC acquired a new position in Alexion Pharmaceuticals during the 2nd quarter valued at about $28,000. Redhawk Wealth Advisors Inc. purchased a new position in shares of Alexion Pharmaceuticals in the 2nd quarter valued at approximately $29,000. Thor Advisors LLC purchased a new position in shares of Alexion Pharmaceuticals in the 1st quarter valued at approximately $34,000. NEXT Financial Group Inc purchased a new position in shares of Alexion Pharmaceuticals in the 2nd quarter valued at approximately $36,000. Finally, Duncker Streett & Co. Inc. acquired a new stake in Alexion Pharmaceuticals in the 2nd quarter worth approximately $39,000. 93.23% of the stock is currently owned by institutional investors.

Shares of ALXN stock traded down $1.73 during trading hours on Wednesday, hitting $107.87. The company’s stock had a trading volume of 453,910 shares, compared to its average volume of 3,067,739. The company has a 50 day moving average of $110.38 and a 200 day moving average of $124.72. The stock has a market cap of $23.86 billion, a PE ratio of 15.21, a price-to-earnings-growth ratio of 1.01 and a beta of 1.67. The company has a current ratio of 4.04, a quick ratio of 3.56 and a debt-to-equity ratio of 0.26. Alexion Pharmaceuticals, Inc. has a 12-month low of $92.56 and a 12-month high of $141.86.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Wednesday, July 24th. The biopharmaceutical company reported $2.64 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.51. The firm had revenue of $1.20 billion during the quarter, compared to analysts’ expectations of $1.18 billion. Alexion Pharmaceuticals had a net margin of 29.64% and a return on equity of 20.23%. The firm’s revenue was up 15.1% compared to the same quarter last year. During the same quarter last year, the company posted $2.07 earnings per share. As a group, analysts anticipate that Alexion Pharmaceuticals, Inc. will post 9.03 earnings per share for the current fiscal year.

ALXN has been the topic of several research analyst reports. BidaskClub raised shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday. Morgan Stanley set a $177.00 price target on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 21st. ValuEngine downgraded shares of Alexion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 8th. Credit Suisse Group dropped their price objective on shares of Alexion Pharmaceuticals from $154.00 to $146.00 and set an “outperform” rating on the stock in a report on Friday, September 6th. Finally, Robert W. Baird set a $165.00 target price on Alexion Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 30th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $161.12.

In other Alexion Pharmaceuticals news, EVP Indrani Lall Franchini sold 4,500 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $132.78, for a total value of $597,510.00. Following the sale, the executive vice president now owns 29,627 shares in the company, valued at approximately $3,933,873.06. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Aradhana Sarin sold 578 shares of the company’s stock in a transaction that occurred on Friday, June 21st. The stock was sold at an average price of $132.00, for a total value of $76,296.00. Following the completion of the sale, the insider now owns 30,201 shares in the company, valued at approximately $3,986,532. The disclosure for this sale can be found here. 4.08% of the stock is currently owned by company insiders.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Featured Story: Why do companies engage in swaps?

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.